Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study.

In the comparison of palbociclib combined with AIs versus fulvestrant, palbociclib plus fulvestrant showed a trend toward superior PFS compared with palbociclib plus AIs, although the difference did not reach statistical significance.

also in 53,322 other papers

Within the current sample size, a consistent trend toward progression-free survival (PFS) benefit was observed in the fulvestrant-based combination therapy group, although this difference did not reach statistical significance ( Figure 5 ).

also in 111,027 other papers